Overview
- The FDA's Pharmacy Compounding Advisory Committee voted 8-6 with one abstention on Thursday, July 23 to recommend adding BPC-157 to the 503A bulks list, a non-binding step that would allow state-licensed pharmacies to compound it for patients with prescriptions.
- Career FDA scientists and staff reviewers urged against loosening restrictions, saying the seven peptides under review lack adequate human clinical trials and pose risks such as contamination, dose uncertainty and immune reactions.
- The panel has not made final rulings on the other six peptides under review — TB-500, KPV, MOTS-c, Semax, Epitalon and Emideltide — and votes on those remain pending.
- Critics raised concerns that several committee members have financial ties to peptide clinics and vendors, while supporters including HHS Secretary Robert F. Kennedy Jr. and telehealth firms argued that regulated compounding would curb a dangerous gray market.
- Any change requires FDA administrative action or rulemaking, so the agency will now review the committee vote, public comments and staff analyses before deciding whether to formally allow compounding or to press for clinical trials and tighter safeguards.